<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="186427">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666835</url>
  </required_header>
  <id_info>
    <org_study_id>2003-29-INJ-9</org_study_id>
    <nct_id>NCT00666835</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients</brief_title>
  <official_title>Randomized, Double-blind, Multicenter, Parallel-group, Equivalence Study to Evaluate the Efficacy and Safety of HX 575 vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hexal AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, multicenter, parallel-group, equivalence study involving
      about 462 clinically stable hemodialysis patients aged 18 years or above suffering from
      anemia and treated previously with a stable dose of ERYPO® intravenously.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this Phase III study is the evaluation of therapeutic equivalence
      of HX575 and a comparator epoetin alfa in the maintenance intravenous treatment of renal
      anemia. Efficacy, dosage and safety of HX575 in the long-term treatment were assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the efficacy and safety of HX 575 and ERYPO®.</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of all and of all drug related AEs Incidence of antibody formation against erythropoietin</measure>
    <time_frame>56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">462</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>HX575 epoetin alfa Hexal AG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients were switched from the comparator to HX575 (erythropoietin alfa) in ratio 2:1 to be intravenously (solution for injection i.v.) treated with HX575 in pre-filled syringes for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ERYPO®, Janssen-Cilag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients were randomized and continued to be treated with ERYPO® in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HX575 Solution for i.v. injection</intervention_name>
    <description>HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin</description>
    <arm_group_label>HX575 epoetin alfa Hexal AG</arm_group_label>
    <other_name>Binocrit, Abseamed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERYPO®, Janssen-Cilag, Germany</intervention_name>
    <description>Solution for i.v. injection</description>
    <arm_group_label>ERYPO®, Janssen-Cilag</arm_group_label>
    <other_name>EPREX®</other_name>
    <other_name>Solution for i.v. injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Receiving dialysis for at least 6 months (3 times weekly) before screening

          -  Age: &gt;=18

          -  Clinically stable, i.e. hemoglobin within the established range (10.0 to 13.0 g/dl)
             for at least 12 weeks before screening

          -  Stable intravenous dosage of ERYPO® three times weekly for at least 8 weeks before
             screening and during screening with a maximal weekly dosage of 300 IU/kg body weight
             (stable is defined as &lt;25% change (up or down) in weekly dose and no change in
             frequency over 8 weeks prior screening and 10 weeks prior randomisation)

          -  Baseline hemoglobin concentration of 10.0 to 13.0 g/dl (mean of two pre-randomization
             pre-dialysis samples of Hb at visit -2 and visit 1)

          -  Serum ferritin &gt;=100 µg/l and/or saturated transferrin levels &gt;=20%

          -  C-reactive protein &lt;15 mg/l (&lt; 5 mg/l: normal; &gt;= 5 mg/l &lt; 10 mg/l: +; &gt;=10mg/l &lt; 100
             mg/l: ++; &gt;=100 mg/l: +++)

          -  Ability to follow study instructions and likely to complete all required visits

          -  Written informed consent of the patient

        Exclusion Criteria:

          -  Anemia of non-renal causes

          -  Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia,
             hematological malignancy, hemolytic anemia)

          -  Evidence of severe hepatic dysfunction (ALT and/or AST above 2 x upper limit of
             normal range; or gamma-GT above 3 x upper limit of normal range)

          -  Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid
             hormone &gt;1500 pg/mL).

          -  Known history of bone marrow disease

          -  Any red blood cell transfusion(s) during the last 12 weeks before screening or during
             the screening/baseline period

          -  Insufficient concomitant iron treatment during the last 2 months before Visit -2

          -  Uncontrolled hypertension, defined as a predialysis diastolic blood pressure
             measurement &gt;=110 mmHg during the screening period

          -  Congestive heart failure [New York Heart Association (NYHA) class III and IV]

          -  Unstable angina pectoris, active cardiac disease, cardiac infarction during the last
             six months before screening

          -  History of blood coagulation disease

          -  Thrombocytopenia (platelet count &lt;100.000/µl)

          -  Leukopenia (white blood cell count &lt; 2.000/µl)

          -  Overt bleeding (acute or chronic bleeding within 2 months of inclusion) or hemolysis

          -  Evidence of acute infectious disease or serious active inflammatory states within one
             months before screening (Visit -2) or during the screening/baseline period

          -  Suspicion or known PRCA (pure red cell aplasia)

          -  Previously diagnosed HIV or acute hepatitis infection

          -  Treatment for epilepsy within the past 6 months

          -  Planned surgery during the next 7 months (except vascular access surgery)

          -  Any androgen therapy within 2 months before visit -2 and during the study

          -  Therapy with immunosuppressants or any drug known to affect the hematocrit within 1
             month before Visit -2 and during the study

          -  Clinical evidence of malignant diseases

          -  Pregnancy, breastfeeding women or women not using adequate birth control measures

          -  Known history of severe drug related allergies

          -  Known allergy to one of the ingredients of the test or reference products or
             hypersensitivity to mammalian-derived products

          -  Simultaneous participation in another clinical study or participation in a study in
             the month preceding the start of this study or previously randomized in this study

          -  Participation in an erythropoietin study in the 3 months preceding screening (visit
             -2)

          -  Any other condition which at the investigator´s discretion may put the patient at
             risk or which may confound the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Haag-Weber, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dialysezentrum Straubing, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Barmherzigen Brüder Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialyseinstitut Graz GmbH</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck, Klinische Abteilung für Nephrologie</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Öffentliches Krankenhaus St. Pölten, I. Med. Abteilung</name>
      <address>
        <city>St. Poelten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines öffentliches Krankenhaus Wiener Neustadt , 2. Interne Abteilung</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung der Stadt Wien, 3. Med. Abteilung</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital der Stadt Wien, Abt. für Nephrologie und Dialyse</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Bad Münder</name>
      <address>
        <city>Bad Münder</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Bergisch Gladbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Bischofswerda</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Drs. Riedasch/Schreiber</name>
      <address>
        <city>Coesfeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Deggendorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis</name>
      <address>
        <city>Donaueschingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Eberswalde</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Stefan Holzmann</name>
      <address>
        <city>Erkelenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. Möller, Dr. Knee</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis</name>
      <address>
        <city>Freiberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Fürstenzell</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Guenzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Gummersbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Sohn und Schaumann</name>
      <address>
        <city>Hameln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Haßfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Stefan Holzmann</name>
      <address>
        <city>Heinsberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kienle</name>
      <address>
        <city>Homberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Ingolstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH - Prof. Dr. med. Heide Sperschneider</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Kronach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr. med. Matthias Anders</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kfh Kuratorium für Dialyse &amp; Nierentransplantation e.V., 2.Etage</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Nierentranplantation und Dialyse e.V.</name>
      <address>
        <city>Lohr</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Prof. Rob, Dr. Wilhelm u. Dr. Schümann</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysepraxis Dr.med. H.-D. Hoffmann</name>
      <address>
        <city>Menden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Neuried</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Noerdlingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr.Steger, Dr.Böhmer, Dr.Kirpal</name>
      <address>
        <city>Nuremberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Oberschleißheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V.</name>
      <address>
        <city>Plauen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dialysezentrum</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres.Hartmann, Schiele</name>
      <address>
        <city>Saarbruecken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Straubing</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KfH Kuratorium für Dialyse und Nierentransplantation e.V</name>
      <address>
        <city>Sulzbach-Rosenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 21, 2016</lastchanged_date>
  <firstreceived_date>April 23, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment of anemia in hemodialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
